Candel Therapeutics Reports $47.8 Million Net Loss and Increased Assets in Latest 10-Q Filing

Candel Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $47.8 million for the first half of 2026, a stark contrast to a net income of $2.6 million during the same period in 2025. This shift is attributed to increased operating expenses, which rose to $43 million from $19.3 million year-over-year, primarily driven by heightened research and development costs associated with its clinical trials for its lead product candidate, aglatimagene.

The company's total assets increased to $208.1 million as of June 30, 2026, up from $125.2 million at the end of 2025, largely due to a substantial rise in cash and cash equivalents, which reached $201.6 million compared to $119.7 million previously. This increase was bolstered by successful capital raises, including a $93.5 million net proceeds from a public offering in February 2026 and $24.2 million from at-the-market offerings under its 2025 Shelf registration. The company’s total liabilities also grew, amounting to $82 million, up from $73.3 million, reflecting increased debt obligations.

Candel Therapeutics has made strategic advancements in its clinical programs, particularly with aglatimagene, which is undergoing pivotal trials for localized prostate cancer. The company has reported positive topline data from these trials, leading to FDA designations that could expedite its path to market. Additionally, the company is expanding its clinical pipeline, with ongoing trials for non-small cell lung cancer and recurrent high-grade glioma, indicating a robust commitment to advancing its product candidates.

Operationally, Candel has increased its workforce to support its expanding clinical and administrative functions, with employee-related expenses rising significantly. The company’s headcount is expected to continue growing as it prepares for potential commercialization of its therapies. As of June 30, 2026, Candel had approximately 76.2 million shares outstanding, reflecting its ongoing equity financing activities.

Looking ahead, Candel Therapeutics anticipates continued operating losses as it invests heavily in clinical development and commercialization readiness. The company expects its existing cash reserves will fund operations into the first quarter of 2028, but acknowledges the need for additional capital to support its ambitious growth plans. The management remains focused on securing further financing through various avenues, including equity offerings and potential collaborations, to sustain its operational momentum and advance its innovative cancer therapies.